


12360
Please type a plus sign (+) inside this box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

be used for all correspondence
after initial filing

Application Number	10/017,754
Filing Date	October 29, 2001
First Named Inventor	Robert A. Henderson
Group Art Unit	
Examiner Name	
Attorney Docket No.	210121.478C18

RECEIVED

MAY 10 2002


TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <ul style="list-style-type: none"> <input type="checkbox"/> Fee Attached 	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Amendment/Response <ul style="list-style-type: none"> <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) 	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Licensing-related Papers Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 (4 sheets)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Cited References (14)	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	<input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Terminal Disclaimer	
	<input type="checkbox"/> Small Entity Statement	
	<input type="checkbox"/> Request for Refund	

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Jeffrey Hundley, Ph.D. 42,676	 00500 PATENT TRADEMARK OFFICE
Signature		
Date		

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	Monica Steinborn	
Signature	Monica Steinborn	Date: 01/18/02



RECEIVED

MAY 10 2002

COPY OF PAPERS
ORIGINALLY FILED

PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Robert A. Henderson et al.
Application No. : 10/017,754
Filed : October 29, 2001
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF LUNG CANCER

Docket No. : 210121.478C18

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jeffrey Hundley, Ph.D.
Registration No. 42,676

JEH:mls

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

FORM PTO-1449 (REV.7-80)	FEB 13 2002	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.478C18	APPLICATION NO. 10/017,754
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Robert A. Henderson et al.		
		FILING DATE October 29, 2001	GROUP ART UNIT	

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	RECEIVED	COUNTRY	TRANSLATION
						YES NO
	BB			MAY 10 2002		
	BC					
	BD			TECH CENTER 1600/2900		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BE		Wu and Noguchi, "Activation of globin gene expression by cDNAs from induced K562 cells," <i>Journal of Biological Chemistry</i> 266(26):17566-17572, September 15, 1991.
BF		Yee et al., "Isolation of tyrosinase-specific CD8 ⁺ and CD4 ⁺ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157:4079-4086, 1996.
BG		
BH		
BI		
BJ		
BK		

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.478C18	APPLICATION NO. 10/017,754
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANTS Robert A. Henderson et al.			
		FILING DATE October 29, 2001	GROUP ART UNIT		

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,589,579	12/31/96	Torczynski et al.	536	23.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AB	WO 98/31799	07/23/98	WIPO	RECEIVED
	AC	WO 98/31799	07/23/98	WIPO (corrected version)	MAY 10 2002
	AD	WO 97/33993	09/18/97	WIPO	TECH CENTER 1600/2900

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

AE		Chen et al., "Isolation and characterization of a novel gene expressed in multiple cancers," <i>Oncogene</i> 12(4):741-751, February 15, 1996.
AF		EMBL Database Accession No. AA948244, May 5, 1998.
AG		EMBL Database Accession No. AA620697, October 16, 1997.
AH		GenBank Accession No. X21973, May 18, 1999.
AI		Güre et al., "Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3," <i>Cancer Research</i> 58(1):1034-1041, March 1, 1998.
AJ		Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8α in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.
AK		Liu et al., "XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma," <i>Cancer Research</i> 60(17):4752-4755, September 1, 2000.
AL		Schena et al., "Quantitative monitoring of gene expression patterns with a complementary DNA microarray," <i>Science</i> 270:467-470, October 20, 1995.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).